---
document_datetime: 2024-07-10 16:23:29
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/pixuvri-h-c-2055-psuv-0015-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing-authorisation_en.pdf
document_name: pixuvri-h-c-2055-psuv-0015-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing-authorisation_en.pdf
version: success
processing_time: 0.8648312
conversion_datetime: 2025-12-19 05:44:31.035696
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

An agency of the European Union

26 June 2014 EMA/CHMP/500946/2014 Committee for Medicinal Products for Human Use (CHMP) Pixuvri Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation International non-proprietary name: pixantrone dimaleate Procedure No.  EMEA/H/C/002055/PSUV/0015 Period covered by the PSUR: 11 May 2013 - 10 November 2013 Medicinal product no longer authorised

●

30 Churchill Place

Canary Wharf

Telephone

+44 (0)20 3660 6000

Send a question via our website

●

London E14 5EU

●

United Kingdom

Facsimile

+44 (0)20 3660 5555

www.ema.europa.eu/contact

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR for Pixuvri, the scientific conclusions of PRAC are as follows:

<!-- image -->

Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing the active substance pixantrone remains favourable but recommends that the terms of the marketing authorisation should be varied as based on the data from the PSUR, updates to section 4.4 and 4.8 of the SmPC with respect to secondary malignancies (specifically AML and MDS) are required. The package leaflet is updated accordingly.The CHMP agrees with the scientific conclusions made by the PRAC. Grounds recommending the variation to the terms of the Marketing Authorisation On the basis of the scientific conclusions for Pixuvri, the CHMP is of the opinion that the benefit-risk balance of the medicinal product containing the active substance pixantrone dimaleate is favourable subject to the proposed changes to the product information. The CHMP recommends that the terms of the Marketing Authorisation(s) should be varied. Medicinal product no longer authorised